The Revolution in Oncology: Antibody Drug Conjugates
Are ADCs truly revolutionary in cancer treatment?
Abstract
Antibody drug conjugates (ADCs) are a new and important class of cancer drugs. Innovations in monoclonal antibodies, linkers and payloads dictate the future of ADCs. This paper describes the structure and mechanism of action of ADCs, focussing on monoclonal antibodies, linkers and cytotoxic payloads, and exploring the different types of each that exist. Ten ADCs that are currently on the market are explored in more detail, looking at the structure and mechanism of each and why they are important in the timeline of innovation of ADCs. Three ADCs that are in clinical trials are then explored, focussing on how the technologies they make use of could inform the future of ADC development.
Read the full article here:
